SCHEMBL9720686

SCHEMBL9720686

CCC(=O)c1cc(C)ccc1C

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.65
KMT2A Q03164 2/20 0.65
TSHR P16473 2/20 0.56
ALDH1A1 P00352 6/20 0.49
KDM4E B2RXH2 2/20 0.48
HSD17B10 Q99714 2/20 0.48
HPGD P15428 2/20 0.48
GLA P06280 1/20 0.48
LMNA P02545 3/20 0.47
MAPT P10636 3/20 0.47
TP53 P04637 1/20 0.47
ALOX15 P16050 1/20 0.47
MAPK1 P28482 1/20 0.47
RAB9A P51151 2/20 0.46
MITF O75030 1/20 0.46
S1PR4 O95977 1/20 0.46
S1PR1 P21453 1/20 0.46
HTT P42858 1/20 0.46
NPSR1 Q6W5P4 1/20 0.46
HSP90AB1 P08238 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31693367 1.00 MEN1 (0.65) MEN1KMT2ATSHRALDH1A1KDM4E
SCHEMBL5568822 0.84 MEN1 (0.71) MEN1KMT2ATSHRALDH1A1KDM4E
SCHEMBL581464 0.83 HSD11B1 (0.54) MEN1KMT2AALDH1A1TP53RAB9A
SCHEMBL11989396 0.82 HSP90AB1 (0.63) MEN1KMT2ATSHRKDM4EHSD17B10
SCHEMBL3686610 0.82 MEN1 (0.62) MEN1KMT2ATSHRALDH1A1KDM4E
SCHEMBL10912991 0.82 MEN1 (0.62) MEN1KMT2ATSHRALDH1A1KDM4E
SCHEMBL29368656 0.82 CSNK2A1 (0.62) MEN1KMT2ATSHRKDM4EHSD17B10
SCHEMBL20367164 0.82 MEN1 (0.62) MEN1KMT2ATSHRALDH1A1KDM4E
SCHEMBL1305878 0.82 CSNK2A1 (0.62) MEN1KMT2ATSHRKDM4EHSD17B10
SCHEMBL405443 0.82 MEN1 (0.62) MEN1KMT2ATSHRALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210380546-A1 VACCINE ADJUVANT THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2021-12-09 US disclosed
US-20210380546-A1 VACCINE ADJUVANT THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2021-12-09 US disclosed
US-20180213793-A1 TREATING WATER STRESS IN PLANTS ROTHAMSTED RESEARCH LIMITED (GB) 2018-08-02 US disclosed
US-20180149972-A1 HIGHLY RESOLVED PHOTOCHEMISTRY BELOW THE DIFFRACTION LIMIT BY MEANS OF SWITCHABLE PHOTO-ENOLIZATION KARLSRUHER INSTITUT FUER TECHNOLOGIE (DE) 2018-05-31 US disclosed
US-9023763-B2 Modification of trehalose-6-phosphate levels in plants ISIS INNOVATION LIMITED (GB) 2015-05-05 US disclosed
CN-103755578-A Preparation method for erythro-structure methoxamine hydrochloride GUANGDONG JIABO PHARMACEUTICAL CO LTD 2014-04-30 CN disclosed
US-8362020-B2 Hepatitis C virus inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2013-01-29 US disclosed
US-7645771-B2 CCR5 antagonists as therapeutic agents SMITHKLINE BEECHAM CORP. (US) 2010-01-12 US disclosed
US-7579500-B2 Method for producing 2,5-dimethylphenyl acetic acid ARCHER-DANIELS-MIDLAND COMPANY (US) 2009-08-25 US disclosed
CN-101243081-A Pyrido[2,3-d]pyrimidine-2,4-diamine compounds as PTP1B inhibitors HOFFMANN LA ROCHE (CH) 2008-08-13 CN disclosed
US-5103022-A Reacting dl-2-methyl-1-(4-trifluoromethylphenyl)-3-pyrrolidino -1-propanone with l-acetylphenylglycine to form corresponding diastereomeric salt, deposition, isolation of l-2-methyl-1-(4-trifluoromethylphenyl)-3-pyrrolidino-1-propanone NIPPON KAYAKU KABUSHIKI KAISHA (JP) 1992-04-07 US disclosed
US-5057535-A Muscle relaxants NIPPON KAYAKU KABUSHIKI KAISHA (JP) 1991-10-15 US disclosed
EP-0243905-B1 1-(omega-[bis-(phenyl)alkoxy]-alkyl)-4-(di-(phenyl)-methyl)piperazines, process for their preparation and medicines containing them RICHTER GEDEON VEGYESZET (HU) 1990-10-10 EP disclosed
EP-0243905-A1 1-(omega-[bis-(phenyl)alkoxy]-alkyl)-4-(di-(phenyl)-methyl)piperazines, process for their preparation and medicines containing them Richter Gedeon Vegyészeti Gyár R.T. (HU) 1987-11-04 EP disclosed
EP-0116787-B1 1,1-DIPHENYLPROPANOL DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM Richter Gedeon Vegyészeti Gyár R.T. (HU) 1987-03-18 EP disclosed
EP-0200942-A2 New derivatives of an aminoketone NIPPON KAYAKU KABUSHIKI KAISHA (JP) 1986-11-12 EP disclosed
US-4605785-A I(DUCE POLYSUBSTRATE MONOOXYGENASE ENZYME SYSTEM OF LIV)R WI HOUT GENTS RICHTER GEDEON VEGYESZETI GYAR RT (HU) 1986-08-12 US disclosed
EP-0116787-A1 1,1-Diphenylpropanol derivatives, process for their preparation and pharmaceutical compositions containing them Richter Gedeon Vegyészeti Gyár R.T. (HU) 1984-08-29 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210380546-A1 VACCINE ADJUVANT IFNG, TLR9, LY96 MEN1 2371/4885KMT2A 4792/4885TSHR 4209/4885
US-20180213793-A1 TREATING WATER STRESS IN PLANTS TREH, PPA1, PPP6C MEN1 4706/4885KMT2A 3612/4885TSHR 2520/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.